PT  - JOURNAL ARTICLE
AU  - Ng’ambi, Wingston
AU  - Estill, Janne
AU  - Jahn, Andreas
AU  - Orel, Erol
AU  - Chimpandule, Tiwonge
AU  - Nyirenda, Rose
AU  - Keiser, Olivia
TI  - Factors associated with the incidence rate of HIV viral rebound among children and adults receiving antiretroviral therapy in Malawi using the Laboratory Management information System: 2011-2020
AID  - 10.1101/2021.10.07.21264672
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.07.21264672
4099  - http://medrxiv.org/content/early/2021/10/10/2021.10.07.21264672.short
4100  - http://medrxiv.org/content/early/2021/10/10/2021.10.07.21264672.full
AB  - Objective To describe the trends in the incidence rate of HIV VL rebound and assess the factors associated with the incidence rate of HIV VL rebound among the persons receiving ART in Malawi between 2011 and 2020.Methods We analyzed routinely collected patient-level HIV VL data extracted from the Malawi Laboratory Management Information System (LIMS). We fitted a multivariable Cox regression model of having HIV VL rebound (>1000 copies/mL) using a forward step-wise selection method, with age and sex entered as a priori variables. We presented both crude and adjusted hazard ratios (aHR) of HIV VL rebound for the various independent variables. Statistical significance was set at P<0.05.Results We evaluated 230,465 adults and children receiving ART and having at least one viral load test between 2011 and 2020. The median time between ART initiation and having a VL sample was 55 months (interquartile range: 25-92). The aHR for having HIV VL rebound were: 0.79 for females (95%CI:0.77-0.80, P<0.001) compared to males, 0.95 (95%CI: 0.94-0.98, P<0.001) for patients from rural compared to urban areas and 0.57 (95%CI:0.56-0.58, P<0.001) for routine compared to targeted VL tests. There was a decreasing trend in the aHR of patients having HIV VL rebound with increasing age.Conclusion This is the first national analysis of Malawi HIV VL data from LIMS. Our findings show the need to take into account the geographic and demographic characteristics of the patients in order to persistently suppress HIV VL and consequently achieve 95% HIV VL suppression by 2030.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by a grant from the Swiss National Science Foundation (no 163878).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Malawi National Health Sciences Research Committee (NHSRC) in Lilongwe, Malawi (protocol#:1669).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request from the corresponding author